New lupus drug anifrolumab put to the test in everyday clinics
NCT ID NCT07424261
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is tracking 125 adults with lupus who are starting a new drug called anifrolumab, given as a shot under the skin. Researchers want to see how many patients achieve remission (no active disease) after 24 months of treatment in real-world clinics, not just in strict research settings. The goal is to understand if this drug works well outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anifrolumab (a drug given as a shot under the skin)
What this could lead to
If successful, this could show that anifrolumab helps more lupus patients reach remission in real-world settings, supporting its use as a standard treatment.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It's also relatively small (125 people) and only follows patients for 24 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGAltenburg, Germany
-
Research Site
RECRUITINGBad Bramstedt, Germany
-
Research Site
RECRUITINGBerlin, Germany
-
Research Site
RECRUITINGChemnitz, Germany
-
Research Site
RECRUITINGErlangen, Germany
-
Research Site
RECRUITINGHeidelberg, Germany
-
Research Site
RECRUITINGHerne, Germany
-
Research Site
RECRUITINGKassel, Germany
-
Research Site
RECRUITINGLeipzig, Germany
-
Research Site
RECRUITINGMeerbusch-Lank, Germany
-
Research Site
RECRUITINGMünchen, Germany
-
Research Site
RECRUITINGPlanegg, Germany
-
Research Site
RECRUITINGSchwerin, Germany
-
Research Site
RECRUITINGTrier, Germany
-
Research Site
RECRUITINGWetzlar, Germany
-
Research Site
RECRUITINGWuppertal, Germany